UK: Brexit - What Vote Leave Means For UK Life Sciences

In this article we consider what we know regarding the consequences of the UK's Leave vote for funding, the regulatory regime for medicines and intellectual property, particularly the patents ecosystem.


There is considerable uncertainty as to when (and, even, whether) the UK will exit the EU (a so-called "Brexit"). Nor do we know the nature of the UK's ongoing relationship with the EU after any Brexit occurs, the specifics of which will impact the landscape for the life sciences sector.

If the UK emerges from Brexit as a member of the European Economic Area (EEA), there will be greater scope for a negotiated continued UK involvement in EU regimes and mechanisms.

Funding for research through European schemes

UK life sciences companies and scientific researchers benefit from various funding schemes. Arguably most relevant for the life sciences sector is Horizon 2020. Described as the biggest ever EU research and innovation programme, Horizon 2020 is making available €80 billion between 2014 and 2020 with the aim of supporting breakthroughs, discoveries and world firsts.

The Innovative Medicines Initiative (IMI) is another funding mechanism for the life sciences sector. Bringing together government (through the EU) and industry (as represented by the European Federation of Pharmaceutical Industries and associations (EFPIA)), its second phase budget for 2014-2024 is €3.3 billion (half coming from Horizon 2020).

Funding for research is also available in the life sciences sector through the European Investment Fund (EIF). Held by the European Investment Bank, other banks and financial institutions and the European Commission, the EIF invests money in venture capital funds that then invest directly in businesses, to promote the creation and development of SMEs.

The European Research Council (ERC) also provides access to funding which supports the underlying science base in the UK.

According to the UK BioIndustry Association, a trade association for UK bioscience, the UK is a net recipient of EU funding for its health research, accessing more funding per capita than any other country.

Outside the EU, the UK is likely to find access to such funding mechanisms significantly reduced. The UK Government's Department for Business, Innovation and Skills has issued a statement on higher education and research following the EU referendum, which includes the following:

"The referendum result has no immediate effect on those applying to or participating in Horizon 2020. UK researchers and businesses can continue to apply to the programme in the usual way. The future of UK access to European research and innovation funding will be a matter for future discussions. Government is determined to ensure that the UK continues to play a leading role in European and international research and innovation."

It is therefore imperative for the UK Government to make clear that, in the event of any Brexit, UK Government funds will be made available to UK-based life sciences research institutions (and across all innovative sectors), in both the private and public sectors, on terms which are equivalent to those available through the European schemes. This is necessary to support and secure the UK's position as a leading research base into the medium and long term, and with it the wider benefits to the UK economy.

Similarly, in the course of the UK's transition through Brexit, funds must be made urgently available in order to ensure that ongoing research programs, which may be dependent upon approval of application(s) for funding from such EU sources, continue to remain viably located in the UK.

Whether venture capital funding for early stage companies might be affected by a Brexit remains to be seen. At the very least, investors might think twice about establishing a new spin-out in the UK. The UK has, in recent times, established itself as a jurisdiction of choice for setting up new life science companies in Europe and it would be a shame, to say the least, to see that change. In the short term we are already aware of transactions being put on hold while parties assess the wider implications of a Brexit.

The regulatory regime for medicines and medical devices

The life sciences sector is one of the most highly regulated industry sectors in the world. The majority of the UK legal frameworks governing medicines (including clinical trials, marketing authorisations, licences to manufacture and pharmacovigilance) and medical devices are based on, or directly apply, EU legislation.

The European Medicines Agency (EMA) is the European regulatory agency in charge of providing EU institutions with scientific advice on medicinal products. It is responsible for the centralised authorisation procedure for human and veterinary products, which results in a single marketing authorisation that is valid in all EU countries, as well as the EEA countries (Iceland, Liechtenstein and Norway). The centralised procedure is compulsory for certain categories of drugs and diseases, optional for others.

Where the centralised authorisation procedure is not compulsory, approval can be obtained from a national regulatory agency, with EU-wide approval still available under a mutual recognition mechanism or decentralised procedure. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) is the national agency in the UK.

Prior to a Brexit, decisions will need to be taken on what procedures will be available to obtain authorisations and what mutual recognition will be available following Brexit. Whether the UK becomes an EEA country will be highly relevant here.

In the short term, the legal frameworks are unaffected by the outcome of the referendum, and EU law will continue to govern the regulatory regimes, as well as the regulatory categorisation of different products and devices. EU law will continue to shape the outcome of UK cases, such as in the recent Court of Appeal decision in R (Blue Bio) v Secretary of State for Health on the boundary between medicines and food supplements.

It seems unlikely that, if the UK were to leave the EU, the government would be in a rush to change much of the law which currently regulates medicines and medical devices. However, EU life sciences law is not standing still. There are significant EU legal reforms due to come into force on a timetable which overlaps the period in which a Brexit might occur. These include important new EU Regulations on medical devices and clinical trials. Given the uncertainty over the timing of a Brexit, there are significant challenges for business in knowing how to prepare for legal changes. There is a risk for the UK that investment and activity in these areas will be diverted to countries where the future regulatory regime is more certain.

The UK has been effective in influencing the shape of EU regulation that impacts the life sciences sector. In this, the UK has been greatly assisted by the reputation and efforts of the MHRA, which is considered to be a world-leading regulator. Outside the EU, the UK will not be able to influence the European framework legislation. However, multinational businesses will need to continue to comply with the European regulatory framework. Moreover, the UK regulatory framework is, in practice, unlikely to diverge materially from the European framework.

Brexit will also most likely increase the volume of regulatory scrutiny to be conducted at the UK level, increasing costs for business and the country.

In addition, the EMA is based in London. It seems inevitable that a Brexit would lead to the EMA moving to a country which is a member of the EU. This would be a significant loss for the UK. Having the EMA located in London puts the UK firmly in the centre of drug regulation in Europe. In short, biopharmaceutical sector regulation is an area in which the UK Government must prioritise the development of strategy to manage a smooth and constructive transition in any Brexit.

Intellectual property and the patents ecosystem


Brexit will not impact the existing system for the grant and enforcement of European patents covering the UK, which will continue. This is because the current system is established by agreements made outside the remit of the EU and EEA. The UK's reputation as a jurisdiction in which patent disputes are heard and resolved in a proportionate manner by experienced and specialist judges, who deliver high quality judgments, will continue.

However, the UK's Leave vote is likely now to delay implementation of the new Unified Patent Court (UPC) and Unitary Patent (UP) system.

In recent years, most member states of the European Union, including the UK, have been working together to introduce the new UPC system to establish, for the first time, a court with jurisdiction to resolve patent disputes spanning much of the EU. The UPC, along with the UP (a new, single patent right of equivalent scope), represents a fundamental change to the patents landscape in Europe. In various ways it supplements, complements and replaces aspects of the existing system.

However, the treaty that establishes the new system (the 'UPC Agreement') mandates (among other things) that participating countries must be members of the EU, that it will enter into force only following ratification by the UK, and that the location of a part of the Court of First Instance (being the part of the court that will deal with life sciences cases) will be in London.

It is theoretically possible that the UK could ratify the UPC Agreement before any Brexit takes effect, in order to get the new system operational. However, we consider this to be unlikely. In any event, the location of part of the Central Division (a part of the Court of First Instance) in London is likely to be considered by the other participating states to be an unsustainable oddity needing correction, by amendment to the UPC Agreement. Some countries could treat this as an opportunity to re-visit the wider negotiations. If the history in this area is anything to go by, agreement could take some time.

Consequently, the UK's Leave vote is, in practice, likely to postpone any change to the current system for grant and enforcement of patents, not just for the UK, but for the whole of Europe. Whether the UK will make the new system operational in the short term, and whether it will be able to negotiate a way of remaining involved in the UPC and UP system in the circumstances of Brexit, remains to be seen.

For more on the consequences of the UK's vote Leave for patents, please see our article " Brexit: what the UK's vote Leave means for the patents ecosystem and UPC".

Supplementary protection certificates

Supplementary Protection Certificates (SPCs) provide for extended patent protection for the active ingredient(s) in medicinal products and plant protection products. SPCs are granted at the national level by the relevant patent office (for the UK, the UKIPO), pursuant to European legislation which has effect across the EU and the EEA.

A Brexit from which the UK does not emerge as a member of the EEA will mean that the UK needs new national legislation to implement its own patent term extension scheme (probably by amending the UK Patents Act 1977) in order for SPC-type protection to continue to be available following Brexit.

Wider intellectual property (IP) rights

A Brexit that sets the UK adrift from the EEA will mean that the UK needs to unpick significant laws in some areas of trade mark and design protection, and legislate new paths. The current unitary (EU-wide) regimes for trade mark and design protection will have to be undone somehow. Should a unitary right be split into two parts, covering the UK and the remaining EU? Or should an existing EU right give its holder a right of seniority in an application for a UK right? The UK needs a strategy on this, and soon.

In relation to designs, businesses that have been relying on unregistered Community protection should consider, as a matter of priority, obtaining registered protection. If you have disclosed the design, the clock is already ticking to get a registration on the books before you are prevented from doing so.

From a practical perspective, businesses should also be aware of the need to ensure that terminology used in licences, settlement agreements, co-existence agreements and other transactional arrangements is now drafted in such a way that the extraction of the UK from the EU and unitary IP right systems can be accommodated without a need to re-open negotiation of the contractual terms. In the course of time, existing arrangements which cover the EU as a defined territory, or which concern EU IP rights, will need to be reviewed in order to consider whether they will remain fit for purpose following Brexit.

For more on the issues raised in relation to intellectual property rights generally, please see our article " Brexit - what next for intellectual property?".

It is also worth noting that tax incentives (including the UK's Patent Box scheme) for the location of research, innovation and development work in the UK should now also be considered as a priority by the UK Government.

Concluding comment

Many sectors will, to a greater or lesser extent, be affected by an exit of the UK from the EU; and the implications for the life sciences sector are potentially significant. The sector has become used to working under laws and regulations which apply on an EU wide basis. Many UK laws, like the Human Medicines Regulations 2012, are EU-based, and many drugs are now authorised under a single authorisation which has brought significant efficiencies to applying for and obtaining marketing authorisations in the EU. The unitary patent and the UPC would have added to those efficiencies and increased the attractiveness of the EU, and therefore the UK, as a place to do business in the sector.

However, irrespective of any Brexit, the UK's wider legal and regulatory structures provide a progressive and outward-looking environment for business. With the right leadership and strategy, this can be built upon further in the event of any Brexit. We have every confidence that the UK will remain a leading global hub for life sciences investment, innovation, research and development.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
3 Oct 2017, Seminar, London, UK

Join us over breakfast for our third retail-focused seminar.

10 Oct 2017, Other, London, UK

Join us for our Real Estate Sector Next Generation networking drinks evening.

12 Oct 2017, Webinar, Birmingham, UK

Join us for an interactive evening exploring the possibilities of implementing digital construction in real life projects.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.